Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Sponsor: Hoffmann-La Roche
Summary
This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Official title: Evaluating Effectiveness and Safety of Glofitamab Based Second-Line Therapy in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter, Cohort Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
300
Start Date
2025-09-29
Completion Date
2029-09-29
Last Updated
2026-04-03
Healthy Volunteers
No
Conditions
Interventions
Glofitamab
Participants will receive glofitamab as part of a cancer-treatment regimen in a real-world setting. No intervention will be administered by study investigators.
Locations (15)
Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center
Tianjin, Tianjin Municipality, China
Peking University Third Hospital
Beijing, China
The First Bethune Hospital of Jilin University
Changchun, China
West China Hospital of Sichuan University
Chengdu, China
Guangdong Provincial People's Hospital
Guangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Shandong Cancer Hospital
Jinan, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
Tianjin Cancer Hospital
Tianjin, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
Wuhan, China
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, China
The First Affiliated Hospital of Xian Jiao Tong University
Xi'an, China
Yantai Yu Huangding Hospital
Yantai, China
Henan Cancer Hospital
Zhengzhou, China